Psyence Biomedical Ltd. Files Form 6-K
Ticker: PBMWW · Form: 6-K · Filed: Dec 3, 2024 · CIK: 1985062
Sentiment: neutral
Topics: sec-filing, 6-k, corporate-reporting
TL;DR
Psyence Biomedical filed a 6-K on Dec 3rd, mostly boilerplate. CEO Neil Maresky signed off.
AI Summary
Psyence Biomedical Ltd. filed a Form 6-K on December 3, 2024, to report a press release. The filing includes the signature of Dr. Neil Maresky, Chief Executive Officer and Director, dated December 3, 2024. The company is incorporated in A6 and its fiscal year ends on March 31.
Why It Matters
This filing indicates routine corporate reporting by Psyence Biomedical Ltd. to the SEC, providing updates to investors.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Psyence Biomedical Ltd. (company) — Registrant
- Dr. Neil Maresky (person) — Chief Executive Officer and Director
- December 3, 2024 (date) — Filing Date
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, and in this instance, it includes a press release as Exhibit 99.1.
Who signed this report on behalf of Psyence Biomedical Ltd.?
Dr. Neil Maresky, Chief Executive Officer and Director, signed the report.
What is the filing date of this report?
The report was filed as of December 3, 2024.
What is Psyence Biomedical Ltd.'s principal executive office address?
The principal executive office is located at 121 Richmond Street West Penthouse Suite 1300, Toronto, Ontario M5H 2K1.
Does Psyence Biomedical Ltd. file annual reports under Form 20-F or Form 40-F?
The filing indicates that the registrant files annual reports under cover of Form 20-F.
Filing Stats: 153 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-12-03 09:41:40
Filing Documents
- tm2429989d1_6k.htm (6-K) — 8KB
- tm2429989d1_ex99-1.htm (EX-99.1) — 25KB
- tm2429989d1_ex99-1img01.jpg (GRAPHIC) — 9KB
- 0001104659-24-124932.txt ( ) — 47KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-41937 Psyence Biomedical Ltd. (Translation of registrant's name into English) 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBIT INDEX EXHIBIT INDEX Exhibit Description 99.1 Press Release SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: December 3, 2024 Psyence Biomedical Ltd. By: /s/ Dr. Neil Maresky Name: Dr. Neil Maresky Title: Chief Executive Officer and Director